<DOC>
	<DOCNO>NCT00667719</DOCNO>
	<brief_summary>This study test safety combination aliskiren/amlodipine/hydrochlorothiazide patient essential hypertension</brief_summary>
	<brief_title>A Long Term Safety Study Test Combination Aliskiren/ Amlodipine / Hydrochlorothiazide Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Outpatients 18 year age old Male female patient eligible . msDBP &amp; msSBP Requirements : For newly diagnosed/untreated patient , msDBP ≥ 100 &lt; 120 mmHg , and/or msSBP ≥ 160 &lt; 200 mmHg Visit 1 Visit 2 . For previously treat patient , msDBP ≥ 100 &lt; 120 mmHg , and/or msSBP ≥ 160 &lt; 200 mmHg Visit 2 , Visit 3 , Visit 4 . For patient require taper previous antihypertensive medication , must meet criterion completely discontinue antihypertensive treatment prior enter treatment phase study . Patients eligible able participate study , consent purpose nature investigation clearly explain ( write inform consent ) . Inability discontinue prior antihypertensive medication safely period 1 week 4 week require protocol . Patients three antihypertensive drug msDBP ≥ 110 mmHg and/or msSBP ≥ 180 mmHg Visit 1 . Patients four antihypertensive drug Visit 1 . Patients msSBP ≥ 200 msDBP ≥ 120 mmHg anytime washout period study Visit 14 must discontinue study . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test ( &gt; = 5 mIU/mL ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>essential hypertension</keyword>
	<keyword>high blood pressure</keyword>
</DOC>